Animal research used weight-based dosing roughly in the range of 10 mcg per kg, which for a 80 kg human would be approximately 800 mcg per day, though extrapolation from rodent to human dose is not straightforward and this is not a clinical recommendation
When individuals lose significant amounts of body fat through semaglutide treatment, the total mass of aromatase-containing tissue decreases, potentially reducing peripheral oestrogen conversion
At the same time, the demand increases due to modern living conditions: chronic stress, environmental pollution, unbalanced diet, and intense sports activities challenge the antioxidant system
However, conclusive evidence supporting these claims remains limited, and more extensive research is needed to substantiate these purported benefits comprehensively
Large clinical trials including LEADER, SUSTAIN-6, and EXSCEL have not identified increased fracture rates with GLP-1 therapy compared to placebo
Some patientsparticularly those with treatment-resistant vertex thinning or diffuse thinningrespond better to higher concentrations (6%, 8%, or even 10% in some compounded formulations)